Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06089018
Other study ID # 62522
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date September 10, 2022
Est. completion date September 10, 2024

Study information

Verified date October 2023
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The goal of this observational study is to assess movement in individuals with Myotonic Dystrophy Type 1 (DM1) and Type 2 (DM2) using digital biomarker tools. The long-term aim of this study is to incorporate these outcomes into clinical trials of DM1 and DM2 therapies. Participants will complete a series of assessments that allow for researchers to measure hand myotonia and walking quality, including a Video Hand Opening Test (VHOT), grip strength, 10 meter walk/run test, 6 minute walk test, Timed Up and Go (TUG), Motor Function Measures-32 (MFM-32) test, and more. These assessments may be recorded to detect and map participants motion and walking patterns. Several patient reported outcome (PROs) questionnaires will also be recorded. Participants may also be asked to monitor exercise and sleep activity at home using an Actigraph wearable device. This study is divided into 2 parts: Part A consists of a single visit. Part B consists of a 1-year longitudinal study with 3 clinical follow-up visits.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 125
Est. completion date September 10, 2024
Est. primary completion date September 10, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years to 90 Years
Eligibility Inclusion Criteria: - Ability to provide informed consent - Age 12-90 years old at the time of informed consent - Genetic confirmation of DM1 or DM2 - Ability to comply with study assessments - Clinically apparent myotonia equivalent to hand opening time of at least 2 seconds, in the opinion of the Investigator - Ambulatory (orthoses allowed, canes and walkers not allowed) and able to walk at least 25 meters at screening Exclusion Criteria: - Ongoing medical condition (e.g. wasting or cachexia, severe anemia) that would, in the opinion of the Investigator, interfere with the conduct or assessments of the study - Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression = 90 days of screening, which in the opinion of the Investigator may interfere with the study procedures - Treatment with an investigational drug, biologic agent, or device within one month of screening, or 5 half-lives of investigational agent, whichever is longer - Inability to comply with study requirements - Other unspecified reasons that, in the opinion of the Investigator or the Sponsor, make the participant unsuitable for enrolment

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Stanford Universtiy Palo Alto California

Sponsors (2)

Lead Sponsor Collaborator
Stanford University Biogen

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Video Hand Opening Time (VHOT) With the use of wearable devices, the participant will be asked to open their hand from a fully fisted position as quickly as possible. This assessment will be recorded with a camera as well. Baseline through month 12
Primary Grip Strength Requires a participant to squeeze a device as hard as possible, while the research team measures how much force is produced. Baseline through month 12
Primary Motor Function Measures (MFM-32) This is a motor function test to assess how well a participant can walk, move, and use their hands. The test includes tasks such as reaching and picking up objects, putting out hands, and taking a step. Baseline through month 12
Primary 10 Meter Walk/Run Test From a standing start, the participant is asked to go 10 meters as quickly as possible, either by walking or running. Ankle braces and orthotics may be used. Baseline through month 12
Primary 6 Minute Walk Test Participant is asked to walk as far as possible within 6 minutes. The participant will be instructed to walk at their normal pace towards a cone, then turn around, continuing to do so for 6 minutes, Ankle braces and orthoses may be used. Baseline through month 12
Primary Timed Up and Go (TUG) The participant will be asked to rise from a chair, walk 3 meters, turn around, return to the chair and sit down. The test will be performed twice, once at a comfortable pace and once at a maximal pace. Assistive devices, orthoses and ankle braces may be used. Baseline through month 12
Primary Time to Ascend and Descend 4 Stairs In this task, the participant will climb up and down 4 stairs as quickly as possible. The manner of ascent/descent and the use of railings will be assessed using quality grades. Baseline through month 12
Primary Timed Supine to Sit This functional assessment is used to assess axial strength. The participant will be asked to move from supine position to sitting on the edge of a table as quickly as possible. The manner of sitting as well as the time it takes to complete the task will be recorded. Baseline through month 12
Primary Step Test This is used to assess standing balance. The participant will be asked to maintain their balance on one leg while the other steps on and off a 7.5cm step as many times as possible within 15 seconds. Baseline through month 12
Primary Walk-12 Questionnaire This questionnaire is used to assess walking ability. Baseline through month 12
Primary DM-ACTIVE Questionnaire This questionnaire is used to assess the impact of DM1 on daily life. Baseline through month 12
Primary The Physical Activity Disability Scale (PADS-R) This questionnaire will assess physical activity. Baseline through month 12
See also
  Status Clinical Trial Phase
Recruiting NCT02880735 - Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy N/A
Recruiting NCT06378216 - Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe]
Completed NCT05662150 - Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1 N/A
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Completed NCT05027269 - Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 1/Phase 2
Completed NCT04712422 - Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1
Recruiting NCT05006924 - Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1
Recruiting NCT04656210 - Myotonic Dystrophy - Vascular and Cognition
Completed NCT04634682 - Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 N/A
Withdrawn NCT06270186 - Evaluation of Cognitive Functions in 20 Patients With Type 1 Myotonic Dystrophy With Virtual Reality Approach N/A
Not yet recruiting NCT06300307 - Study of ATX-01 in Participants With DM1 Phase 1/Phase 2
Completed NCT02729597 - Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study N/A
Recruiting NCT06138743 - Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Phase 1
Not yet recruiting NCT05532813 - Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease) Phase 3
Active, not recruiting NCT04886518 - Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Phase 2
Completed NCT05036447 - Myotonic Dystrophy Type 1 and Resistance Exercise N/A
Recruiting NCT03424460 - Venous Thromboembolism in Myotonic Dystrophy Type 1 N/A
Recruiting NCT05865483 - Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)
Completed NCT04001920 - Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 N/A
Completed NCT02858908 - Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Phase 2